- May 22, 2012 | BY
Charles River Principal Scientist Shawna M. Jackman’s recent post to GEN’s blog on “10 Tips for Translational Stem Cell Therapy Research”.
- May 15, 2012 | BY
Charles River bone expert Susan Y. Smith discusses the skeleton’s function in human physiology in Emerging Insights into the Role of the Skeleton, featured in a recent edition of GEN.
- May 7, 2012 | BY
It appears the ‘glue’ in our brains has much to do with genius.
- April 16, 2012 | BY
A new research model, developed by our scientists at Discovery Research Services, simply allows rats to grow old and age into their ‘twilight years’, approximately 20 months in case you were wondering.
- April 3, 2012 | BY
ABC News Medical Unit blog features Charles River scientists’ research on lab mice nesting behavior.
- March 20, 2012 | BY
Whether it’s learning to play the guitar, the piano or how to manage people, there are four stages one must journey through in skill development, the final being “The Master”–someone who’s unconsciously competent.
- March 6, 2012 | BY
On February 9th, 2012, the FDA published recommendations for the development of biosimilars. For 60 days, these draft guidance documents will be open for comments and questions, many of which could ultimately affect the final guidance. There are three basic points to consider when developing biosimilars:
(1) Biosimilarity can be demonstrated using an analytical, animal, or ...
- February 27, 2012 | BY
OpenArray®, a PCR platform in chip form the size of a standard microscope slide and containing individual PCR assays in a high-density format is transforming how health monitoring is viewed and implemented.
- February 14, 2012 | BY
Introduction Because cell therapies are mostly human in origin, they are challenging to study in animals (due to tissue rejection). But, these studies are required before starting human trials. Cells are also unlike chemically identical molecules in a standard drug product. That is, they are always a mixture and are always changing in nature, so ...
- January 30, 2012 | BY
While not necessary for most systemic preclinical toxicology studies, the addition of supplemental specialized ocular endpoints may be warranted if a compound belongs to a class known for potential ocular side effects. Supplemental endpoints may also be warranted in the early screening phase in order to weed out the most problematic compounds.
The key is to ...